Aptagen, LLC
RNA
Alpha-V Beta-3
Protein
N/A nM (reported value)
Washed with PBS and 0.9 mM CaCl2, 0.5 mM MgCl2, 2.67 mM KCl, 1.47 mM KH2PO4, 135 mM NaCl, and 8 mM Na2.
37°C
NA If the oligo is a known aptamer sequence: For binding studies, perform a refolding protocol to ensure proper function (i.e. binding to antigen or target). Refer to the aptamer reference source for the appropriate refolding parameters and binding conditions. Note: it is unknown whether aptamer functions properly without refolding.
See also PF377 P-Selectin Aptamer for an aptamer that also decreases sickled RBC binding to HUVECs.
Endothelial Integrin Alpha-V Beta-3 (Clone 17.16) (ID# 222)
5'rUprUprCprAprAprCprGprCprUprGprUprGprAprAprGprGprGprCprUprUprAprUprAprCprGprAprGprCprGprGprAprUprUprAprCprCprCp3'
37
11855.18 g/mole
364200 L/(mole·cm)
51.35%
2.75
32.55
Note: Information on this aptamer oligo was obtained from the literature and hasn't been validated by Aptagen.
Brunette et al. "RNA Aptamer Therapy for Vaso-Occlusion in Sickle Cell Disease." Nucleic Acids Therapeutics, 21(2011): 275-283. Mi et al. "Targeted inhibition of av??3 integrin with an RNA aptamer impairs endothelial cell growth and survival." Biochemical and Biophysical Research Communications, 338(2005): 956-963.
Have your aptamer oligo synthesized ORDER NOW
We are always looking for ways to improve. Please tell us what you think.